ENDP - Endo International plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD
11.15
-0.07 (-0.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close11.22
Open11.26
Bid11.10 x 1000
Ask11.30 x 100
Day's range11.09 - 11.34
52-week range5.27 - 12.54
Volume1,829,672
Avg. volume6,386,154
Market cap2.495B
Beta-0.17
PE ratio (TTM)N/A
EPS (TTM)-10.60
Earnings date8 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.09
Trade prices are not sourced from all markets
  • Drug Firms Blame Opioid Crisis on Illicit Websites, Dealers
    Bloomberg2 days ago

    Drug Firms Blame Opioid Crisis on Illicit Websites, Dealers

    Two pharmaceutical companies say the real culprits in the opioids epidemic are illegal dealers of the painkillers and want them to be on the hook financially for any damages potentially assessed against drugmakers. Endo International Plc and Mallinckrodt Plc sued a host of convicted drug dealers and Internet sites this week for illegally offering opioids. Among them: RxCash.Biz, which offers misbranded opioids online, an Italian man indicted for of operating so-called pill mills, and a Tennessee resident who’s serving 10 years for possessing fentanyl with an intent to distribute.

  • What Endo International’s Valuation Trend Indicates
    Market Realist9 days ago

    What Endo International’s Valuation Trend Indicates

    Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.

  • Endo’s Generic and International Segments Declined in Q1 2018
    Market Realist9 days ago

    Endo’s Generic and International Segments Declined in Q1 2018

    Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.

  • Analyzing Endo International’s Financial Performance
    Market Realist9 days ago

    Analyzing Endo International’s Financial Performance

    Endo International (ENDP) generated revenues of $700.5 million in the first quarter compared to $1.04 billion in Q1 2017. Endo International incurred a cost of revenues of $403.59 million in the first quarter compared to $668.96 million in Q1 2017. Its gross profit was $296.93 million in the first quarter compared to $368.64 million in Q1 2017.

  • Endo International’s Specialty and Established Products in Q1
    Market Realist9 days ago

    Endo International’s Specialty and Established Products in Q1

    Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.

  • What Analysts Think of Endo International
    Market Realist9 days ago

    What Analysts Think of Endo International

    Of the 19 analysts covering Endo International (ENDP) stock in July, four of them have given the stock a “buy” or higher rating, 14 have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.74 with a target price of $8.53. Sixteen of the 20 analysts covering Abbott Laboratories (ABT) in July have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $69.

  • Is Endo International a Great Stock for Value Investors?
    Zacks18 days ago

    Is Endo International a Great Stock for Value Investors?

    Let???s see if Endo International (ENDP) stock is a good choice for value-oriented investors right now from multiple angles.

  • Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
    Zacks22 days ago

    Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

    Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

  • Reuters - UK Focuslast month

    UK's Indivior will fight U.S. FDA's approval for copycat drug

    Britain's Indivior (Frankfurt: 2IVA.F - news) on Friday vowed to pursue all legal options and seek an immediate injunction against the U.S. Food and Drug Administration's (FDA) decision to approve the first copycat versions of its best-selling opioid addiction treatment. India's Dr Reddy's Laboratories and U.S.-based Mylan NV received FDA approval on Thursday for a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue. Generic rivals in tablet form are already on the U.S. market, which is grappling with an opioid addiction epidemic that killed 33,000 people in 2015, but Suboxone Film leads the market with its version which is placed under the tongue to suppress cravings.

  • Market Realistlast month

    Why Endo International Stock Rose 5.5% on June 12

    On June 11, after the markets closed, Endo International (ENDP) announced that its subsidiaries Endo Pharmaceuticals and Auxilium Pharmaceuticals have entered into a master settlement agreement. This agreement is intended to resolve all known TRT (testosterone replacement therapy) product liability claims the company faces. The company said that the agreement isn’t expected to increase Endo’s product liability reserve, as the company has already recorded an accrual for the settlement in Q4 2017.

  • CNBClast month

    Cramer's lightning round: I can't get people to buy Alibaba's stock

    Jim Cramer laments investors' distaste in the e-commerce conglomerate while taking questions in the lightning round.

  • Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?
    Zackslast month

    Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?

    Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Endo International plc (NASDAQ:ENDP): Is Breakeven Near?
    Simply Wall St.last month

    Endo International plc (NASDAQ:ENDP): Is Breakeven Near?

    Endo International plc’s (NASDAQ:ENDP): Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. With the latest financial yearRead More...

  • Why Endo International plc Rocketed Higher Today
    Motley Foollast month

    Why Endo International plc Rocketed Higher Today

    Traders take the generic-drug maker on a ride.

  • Barrons.com2 months ago

    Valeant, Endo Both Buys in Specialty Pharma

    Deutsche Bank's Gregg Gilbert takes a look at the specialty-pharmaceutical sector on Friday, writing that Valeant Pharmaceuticals International (VRX) and Endo International (ENDP) both look poised for more gains. Gilbert reiterated a Buy rating on Valeant and raised his price target by $2 to $25, based on more upbeat estimates for irritable-bowel drug Xifaxan, currently its biggest seller at around1 13% of sales. As for Endo, Gilbert reiterated a Buy rating as well, although he did lower his price target by $2 to $10.

  • BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
    Zacks2 months ago

    BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

    BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

  • Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
    Zacks2 months ago

    Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

    Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.

  • Barrons.com2 months ago

    Valeant Upside, Shire Buyout Don't Rally Pharma Stocks

    Some pharma stocks are on the rise today, following earnings and Shire's (SHPG) $62 billion takeover deal, but the goodwill didn't spread to all regions of the sector. Valeant Pharmaceuticals International (VRX) delivered a beat-and-raise first quarter, saying it earned 89 cents a share on revenue of $2 billion, while analysts expected EPS of 60 cents on revenue of $1.95 billion. For the full year, it now sees revenue of $8.15 billion to $8.35 billion, up from its previous $8.1  billion-$8.3 billion range, and above the $8.23 billion consensus estimate.

  • Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

    Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

  • MarketWatch2 months ago

    Endo shares rise 5% after Q1 profit, revenue beats

    Endo International PLC shares rose 5% in premarket trade Tuesday after the company reported first-quarter profit and revenue that came in above FactSet expectations. The company also affirmed its 2018 revenue guidance of $2.6 billion to $2.8 billion and 2018 guidance for adjusted EPS from continuing operations of $2.15 to $2.55.

  • Reuters - UK Focus3 months ago

    Indivior's Q1 profit slips, shares fall on top drug let-down

    Britain's Indivior (Frankfurt: 2IVA.F - news) posted a drop in first-quarter profit, as its blockbuster treatment, Suboxone Film, lost market share in the U.S. due to stiff competition from generic versions, the maker of drugs that treat opioid addiction said. Shares in Indivior, which was spun out from Reckitt Benckiser in 2014 and has risen about three-fold since, were down as much as 6 percent in early trading before clawing back most of it to trade 1.3 percent down on Wednesday.

  • Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?
    Zacks3 months ago

    Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?

    Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.

  • What Falling Estimates & Price Mean for Endo International (ENDP)
    Zacks4 months ago

    What Falling Estimates & Price Mean for Endo International (ENDP)

    Endo International (ENDP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

  • Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report?
    Zacks4 months ago

    Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report?

    Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes